9 Biocon expects to file commercialisation application for its biosimilars (Glargine, Trastuzumab,Pegfilgrastimandinsulin)intheUSandEuropeinFY17 Keyhighlights:Modest10%salesgrowthtoRs8.25bn(estimatedRs8.44bn),duetoslow...